Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus Dalgleish

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cancer Gene Therapy|April 2, 2005
Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapyHardev Pandha, Jonathan Eaton, Rebecca Greenhalgh, et al.
Nature Reviews. Urology|January 31, 2020
Mycobacterial immunotherapy for prostate cancer: where can we go from here?Vasilis Stavrinides, Angus Dalgleish, John P Copier, et al.
Frontiers in Immunology|January 30, 2023
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapyLaura A Ridgley, Jonathan Caron, Angus Dalgleish, et al.
Frontiers in Bioscience (Landmark Edition)|June 2, 2012
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancerNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Frontiers in Oncology|September 26, 2022
Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hopeChristine Galustian, Angus Dalgleish, Mark Bodman-Smith, et al.
BMC Cancer|February 2, 2013
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cellsNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2011
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activationEdit Kovalcsik, Katie Lowe, Mike Fischer, et al.
International Journal of Oncology|January 20, 2016
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibitionNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Cancer Immunology, Immunotherapy : CII|August 23, 2002
Immunotherapeutic potential of whole tumour cellsStephen Ward, David Casey, Marie-Christine Labarthe, et al.
Oncology Reports|October 25, 2024
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinomaOzlem Sherif, Said A Khelwatty, Izhar Bagwan, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cancer Gene Therapy|April 2, 2005
Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapyHardev Pandha, Jonathan Eaton, Rebecca Greenhalgh, et al.
Nature Reviews. Urology|January 31, 2020
Mycobacterial immunotherapy for prostate cancer: where can we go from here?Vasilis Stavrinides, Angus Dalgleish, John P Copier, et al.
Frontiers in Immunology|January 30, 2023
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapyLaura A Ridgley, Jonathan Caron, Angus Dalgleish, et al.
Frontiers in Bioscience (Landmark Edition)|June 2, 2012
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancerNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Frontiers in Oncology|September 26, 2022
Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hopeChristine Galustian, Angus Dalgleish, Mark Bodman-Smith, et al.
BMC Cancer|February 2, 2013
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cellsNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2011
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activationEdit Kovalcsik, Katie Lowe, Mike Fischer, et al.
International Journal of Oncology|January 20, 2016
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibitionNikolaos Ioannou, Alan M Seddon, Angus Dalgleish, et al.
Cancer Immunology, Immunotherapy : CII|August 23, 2002
Immunotherapeutic potential of whole tumour cellsStephen Ward, David Casey, Marie-Christine Labarthe, et al.
Oncology Reports|October 25, 2024
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinomaOzlem Sherif, Said A Khelwatty, Izhar Bagwan, et al.
Pageof 5